109 related articles for article (PubMed ID: 12039590)
1. Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.
Calderwood DJ; Johnston DN; Munschauer R; Rafferty P
Bioorg Med Chem Lett; 2002 Jun; 12(12):1683-6. PubMed ID: 12039590
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE
Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
Burchat AF; Calderwood DJ; Friedman MM; Hirst GC; Li B; Rafferty P; Ritter K; Skinner BS
Bioorg Med Chem Lett; 2002 Jun; 12(12):1687-90. PubMed ID: 12039591
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
[TBL] [Abstract][Full Text] [Related]
5. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
[TBL] [Abstract][Full Text] [Related]
6. 4-thiophenoxy-N-(3,4,5-trialkoxyphenyl)pyrimidine-2-amines as potent and selective inhibitors of the T-cell tyrosine kinase p56lck.
Moffat DF; Allen RA; Rapecki SE; Davis PD; O'Connell J; Hutchings MC; King MA; Boyce BA; Perry MJ
Curr Med Chem; 2004 Mar; 11(6):747-53. PubMed ID: 15032728
[TBL] [Abstract][Full Text] [Related]
7. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
8. Disubstituted pyrimidines as Lck inhibitors.
Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
10. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
[TBL] [Abstract][Full Text] [Related]
11. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
Nyakeriga AM; Garg H; Joshi A
Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
[TBL] [Abstract][Full Text] [Related]
13. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
14. The protein tyrosine kinase p56(lck) regulates the serine-base exchange activity in Jurkat T cells.
Marhaba R; Dumaurier MJ; Pelassy C; Batoz M; Peyron JF; Breittmayer JP; Aussel C
FEBS Lett; 1997 Mar; 405(2):163-6. PubMed ID: 9089283
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2.
Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Che J; Lee CC; Caldwell J; Kanazawa T; Umemura I; Matsuura N; Ohmori O; Honda T; Gray N; He Y
Bioorg Med Chem Lett; 2006 May; 16(10):2689-92. PubMed ID: 16524731
[TBL] [Abstract][Full Text] [Related]
16. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
[TBL] [Abstract][Full Text] [Related]
17. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
[TBL] [Abstract][Full Text] [Related]
18. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
19. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
Bamborough P; Angell RM; Bhamra I; Brown D; Bull J; Christopher JA; Cooper AW; Fazal LH; Giordano I; Hind L; Patel VK; Ranshaw LE; Sims MJ; Skone PA; Smith KJ; Vickerstaff E; Washington M
Bioorg Med Chem Lett; 2007 Aug; 17(15):4363-8. PubMed ID: 17600705
[TBL] [Abstract][Full Text] [Related]
20. Lck Inhibits Heat Shock Protein 65-Mediated Reverse Cholesterol Transport in T Cells.
Luo T; Hu J; Xi D; Xiong H; He W; Liu J; Li M; Lu H; Zhao J; Lai W; Guo Z
J Immunol; 2016 Nov; 197(10):3861-3870. PubMed ID: 27742830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
